The CpG island of the ST3Gal II promoter was hypermethylated under androgen-depleted conditions and was demethylated by androgen treatment in hormone-sensitive prostate cancer cells (Fig. 4). The gene discussed is ST3GAL2; the disease is prostate carcinoma.